Allicin attenuates necrotizing enterocolitis via PINK1/Parkin-mediated mitophagy to suppress pyroptosis

Oct 31, 2025International immunopharmacology

Allicin reduces severe intestinal inflammation by promoting damaged mitochondria cleanup to prevent cell death

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Allicin treatment significantly reduces mortality in neonatal rats with necrotizing enterocolitis (NEC).

Allicin improves cell viability and reduces cytotoxicity in an in vitro NEC model using IEC-6 cells.
It inhibits apoptosis and promotes proliferation while suppressing inflammation and oxidative stress markers.
In a 3D intestinal organoid model, allicin enhances organoid budding and restores epithelial barrier integrity.
Allicin's protective effects are associated with activation of the PINK1/Parkin-dependent mitophagy pathway.
Mitophagy inhibition largely diminishes the therapeutic benefits of allicin, indicating its necessity for protection in NEC.

AI simplified

Necrotizing enterocolitis (NEC) is a common and severe gastrointestinal disease in neonates, with unclear pathogenesis and limited therapeutic options. This study explores the intestinal protective effects of allicin in NEC and its potential molecular mechanisms. In lipopolysaccharide (LPS)-induced in vitro NEC model using IEC-6 cells, allicin significantly improved cell viability, reduced cytotoxicity, inhibited apoptosis, promoted proliferation, and suppressed ROS overproduction and inflammatory responses (IL-1β, IL-6, IL-18, TNF-α). Expanding to a physiologically relevant 3D intestinal organoid model mimicking NEC pathology, allicin enhanced organoid budding efficiency and proliferative capacity while restoring epithelial barrier integrity through E-cadherin upregulation, highlighting its ability to repair multicellular structural damage. In a neonatal rat NEC model, allicin treatment reduces mortality in NEC rats, alleviates intestinal pathological damage, and restores intestinal barrier integrity while suppressing intestinal inflammation and pyroptosis, as evidenced by downregulated NLRP3, Cleaved-Caspase-1, and N-terminal-GSDMD expression. Notably, the therapeutic benefits of allicin were largely abolished by the mitophagy inhibitor 3-MA at both cellular and animal levels, underscoring the necessity of mitophagy for its protective effects. Mechanistic studies indicate that allicin activates the PINK1/Parkin-dependent mitophagy pathway, effectively reducing mitochondrial ROS levels and inhibiting pyroptosis. Furthermore, genetic knockdown of PINK1 or Parkin partially reversed allicin-mediated cytoprotection, ROS reduction, and anti-pyroptotic effects, definitively establishing PINK1/Parkin-dependent mitophagy as the crucial pathway. Our findings provide substantial theoretical and scientific support for the potential of allicin as a therapeutic agent for NEC.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Allicin attenuates necrotizing enterocolitis via PINK1/Parkin-mediated mitophagy to suppress pyroptosis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief